Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.

ABSTRACT:

Purpose

Programmed death ligand 1 [PD-(L)1]-targeted therapies have shown modest survival benefit in triple-negative breast cancer (TNBC). PD-L1⁺ microenvironments in TNBC are not well characterized and may inform combinatorial immune therapies. Herein, we characterized clinicopathologic features, RNA-based immune signatures, and spatially defined protein-based tumor-immune microenvironments (TIME) in early-stage PD-L1⁺ and PD-L1^- TNBC.

Experimental design

From a large cohort of chemotherapy-naïve TNBC, clinicopathologic features, deconvoluted RNA immune signatures, and intraepithelial and stromal TIME (Nanostring GeoMX) were identified in subsets of PD-L1⁺ and PD-L1^- TNBC, as defined by FDA-approved PD-L1 companion assa

SUBMITTER: Carter JM 

PROVIDER: S-EPMC8808363 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature